Taraxerol acetate 

Taraxerol acetate is a COX-1 and COX-2 inhibitor with IC₅₀ values of 116.3 μM and 94.7 μM, respectively. Taraxerol acetate the has the anticancer potential and induces cell apoptosis^[1].

Taraxerol acetate(10-150 µM; 24 or 48 hours) induces a dose- and time-dependent cytotoxic effects in the U87 cells, exhibits IC₅₀ values of 34.2 and 28.4 µM, at 24 and 48 h, respectively^[2].
Taraxerol acetate(10, 50 and 150 µM; 24 hours) induces cell apoptosis, the percentage of apoptotic cells increased from 7.3% in the control cells, to 16.1, 44.1 and in the 10, 50 and 150 µM taraxerol acetate-treated cells, respectively. Furthermore, taraxerol acetate treatment led to sub-G1 cell cycle arrest with a corresponding decrease in the number of S-phase cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

468.75

C₃₂H₅₂O₂

2189-80-2

C[C@]12C3=CC[C@@](C)(CCC(C)(C)C4)[C@]4([H])[C@@]3(CC[C@]1([H])[C@@]5([C@@](C(C)([C@@H](OC(C)=O)CC5)C)([H])CC2)C)C

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ubaid Ur Rehman1 A, et al. Molecular docking of taraxerol acetate as a new COX inhibitor. Journal of the Bangladesh Pharmacological Society

  [2]. Hong JF, et al. Anticancer activity of taraxerol acetate in human glioblastoma cells and a mouse xenograft model via induction of autophagy and apoptotic cell death, cell cycle arrest and inhibition of cell migration.Mol Med Rep. 2016 Jun;13(6):4541-8.  [Content Brief]